Tessa Therapeutics Completes US$126 Million Financing Led by Polaris Partners
Tessa Therapeutics, a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced the close of a US$126 million Series A financing round.